Biodegradable nanoparticles for the treatment of epilepsy: From current advances to future challenges

dc.contributor.authorBonilla Vidal, Lorena
dc.contributor.authorEsteruelas Navarro, Gerard
dc.contributor.authorEttcheto Arriola, Miren
dc.contributor.authorEspina García, Marta
dc.contributor.authorGarcía López, María Luisa
dc.contributor.authorCamins Espuny, Antoni
dc.contributor.authorSouto, Eliana B.
dc.contributor.authorCano Fernández, Amanda
dc.contributor.authorSánchez-López, E. (Elena)
dc.date.accessioned2022-02-10T07:47:16Z
dc.date.available2022-02-10T07:47:16Z
dc.date.issued2021-12-04
dc.date.updated2022-02-10T07:47:16Z
dc.description.abstractEpilepsy is the second most prevalent neurological disease worldwide. It is mainly characterized by an electrical abnormal activity in different brain regions. The massive entrance of Ca2+ into neurons is the main neurotoxic process that lead to cell death and finally to neurodegeneration. Although there are a huge number of antiseizure medications, there are many patients who do not respond to the treatments and present refractory epilepsy. In this context, nanomedicine constitutes a promising alternative to enhance the central nervous system bioavailability of antiseizure medications. The encapsulation of different chemical compounds at once in a variety of controlled drug delivery systems gives rise to an enhanced drug effectiveness mainly due to their targeting and penetration into the deepest brain region and the protection of the drug chemical structure. Thus, in this review we will explore the recent advances in the development of drugs associated with polymeric and lipid-based nanocarriers as novel tools for the management of epilepsy disorders. Keywords: epilepsy; lipid nanoparticles; nanomedicine; nanotechnology; neurodegenerative diseases; polymeric nanoparticles.
dc.format.mimetypeapplication/pdf
dc.identifier.idgrec716441
dc.identifier.issn2470-9239
dc.identifier.urihttps://hdl.handle.net/2445/183043
dc.language.isoeng
dc.publisherJohn Wiley & Sons
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.1002/epi4.12567
dc.relation.ispartofEpilepsia Open, 2021
dc.relation.urihttps://doi.org/10.1002/epi4.12567
dc.rightscc-by-nc-nd (c) Bonilla, Lorena et al., 2021
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/4.0/
dc.sourceArticles publicats en revistes (Farmàcia, Tecnologia Farmacèutica i Fisicoquímica)
dc.subject.classificationEpilèpsia
dc.subject.classificationNanopartícules
dc.subject.classificationMalalties neurodegeneratives
dc.subject.classificationNanotecnologia
dc.subject.otherEpilepsy
dc.subject.otherNanoparticles
dc.subject.otherNeurodegenerative Diseases
dc.subject.otherNanotechnology
dc.titleBiodegradable nanoparticles for the treatment of epilepsy: From current advances to future challenges
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
716441.pdf
Mida:
523.43 KB
Format:
Adobe Portable Document Format